V1RE12 Inhibitors
V1RE12 inhibitors represent a class of chemical compounds characterized by their specific interaction with a certain biological target, identified by the code V1RE12, which is a molecular structure within a biological system. The precise nature of V1RE12 is not disclosed in this context, but inhibitors, in general, are substances that bind to a biological molecule and impede its normal function. Typically, this interaction involves a lock-and-key mechanism where the inhibitor has a complementary shape to a specific part of the target molecule, often an active site. The binding can be reversible or irreversible, depending on the nature of the interaction between the inhibitor and its target. In reversible inhibition, the inhibitor can dissociate from the target molecule, allowing the target to potentially return to its normal function. Conversely, irreversible inhibitors form stable, often covalent bonds with their targets, which can permanently alter the target's activity.
Chemically, V1RE12 inhibitors could encompass a broad range of molecular structures, from simple, small molecules to complex, large biomolecules. The design of these inhibitors is guided by the structural details of the V1RE12 target, ensuring a high degree of specificity. The inhibitors can be designed to mimic the natural substrate of the target, to compete with it and thereby block its binding, or they might be designed to bind to different sites on the target molecule to induce a conformational change that reduces its normal activity. The interaction between V1RE12 inhibitors and their target is often characterized by affinity, which is the strength of the interaction, and by kinetics, which describes the rate of association and dissociation between the inhibitor and the target. The development of these inhibitors involves sophisticated techniques such as computational modeling, medicinal chemistry, and various high-throughput screening methods to identify molecules with the desired properties. The specificity and selectivity of V1RE12 inhibitors are critical, as these determine the extent to which the inhibitors will interact with the intended target versus other, unintended targets, which is a crucial factor in their characterization.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the resulting complex inhibits mTOR, a kinase involved in cell growth and proliferation. When mTOR is inhibited, it can lead to reduced protein synthesis and cellular metabolism, which may decrease V1RE11 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is crucial for the activation of AKT signaling pathway. By inhibiting PI3K, AKT phosphorylation and subsequent activation are reduced, potentially diminishing the functional activity of V1RE11. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK1, which in turn prevents the activation of ERK1/2 MAPKs. This inhibition may affect downstream signaling events that could regulate the activity of V1RE11 through transcriptional or post-translational modifications. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2 which are upstream regulators of ERK1/2 MAPKs. Inhibition of this pathway can lead to alteration in cell cycle progression and gene expression that may indirectly affect the activity of V1RE11. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway is involved in stress responses and inflammation. Inhibiting p38 MAPK can alter cellular responses to stress and cytokines, potentially decreasing the activity of V1RE11. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK family that regulates apoptosis, cell proliferation, and cytokine production. Inhibition of JNK signaling could lead to changes in these cellular processes that might inhibit V1RE11 function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the proliferation and survival of certain cell types. This could lead to a reduction in pathways that are potentially regulating V1RE11 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets multiple receptors including RAF, VEGFR, and PDGFR. By inhibiting these pathways, it may decrease signaling events that lead to the activation of V1RE11. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor which interferes with chromosome alignment and segregation during mitosis. Disruption of mitotic events could indirectly decrease the functional activity of V1RE11. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that impedes the degradation of protein substrates, affecting cellular homeostasis and signaling. This can lead to a buildup of proteins that may negatively regulate the activity of V1RE11. | ||||||